Merck Animal Health Completes Acquisition of Quantified Ag®

June 17, 2020 |

5 min read

Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA, announced the completion of its acquisition of Quantified Ag®, a leading data and analytics company that monitors cattle body temperature and movement in order to detect illness early.

June 17, 2020 20:30 UTC

Broadens Livestock Digital Portfolio to Improve Animal Well-being Through Connected Technology

MADISON, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its acquisition of Quantified Ag^®, a leading data and analytics company that monitors cattle body temperature and movement in order to detect illness early. In April 2018, Merck Animal Health invested in Quantified Ag^® and partially funded their development work in data analytics in livestock. Specific terms of the agreement were not disclosed.

Today’s announcement further positions Merck Animal Health as a global leader in animal health, broadening its portfolio in connected technology to improve cattle health outcomes by leveraging data and analytics for animal health and well-being. Quantified Ag^®, located in Lincoln, Nebraska, provides a pro-active system for cattle producers and feedlot operators to track an animal’s biometrics and behavioral data through a non-invasive cattle ear tag equipped with sensors to monitor the health of the individual animal or herd. The technology can detect animal illness, thus reducing the potential for disease outbreak, allowing for easy identification of sick animals, and providing easy-to-use software reports on any mobile device, desktop, tablet or secure website. Proprietary algorithms are able to identify animals showing signs of illness or disease and provide real-time alerts.

Quantified Ag^® product portfolio will join the Allflex Livestock Intelligence business unit within Merck Animal Health. Allflex Livestock Intelligence is a complementary business that specializes in identification and monitoring technology that delivers real-time, actionable data and insights to help improve livestock management.

“We are pleased to take this step forward with Quantified Ag^® as we continue to broaden our portfolio with complementary products and technologies to advance animal well-being for our customers,” said Rick DeLuca, president, Merck Animal Health. “Our goal is to improve the detection of animal illness, and the responsible use of treatments to maintain the health of livestock. We are at the technological forefront of shaping the future of animal health through our commitment to leveraging our scientific and technical capabilities and expertise through comprehensive solutions to manage the health and well-being of animals.”

New digitally based tools that enable rapid large-scale, data capture coupled with powerful data management platforms for rapid analysis and monitoring are transforming the farming and companion animal industries. This more informed approach to animal health and disease prevention is facilitating improved process management, thereby enhancing yields, overall efficiency and sustainability while complementing the portfolio of veterinary pharmaceuticals and vaccines at Merck Animal Health.

Vishal Singh, co-founder and chief executive officer, Quantified Ag^®, said, “We believe that Merck Animal Health is the right company, ideally positioned to keep developing our products in a sustainable manner. We’ve enjoyed a collaborative partnership over the past few years and are pleased with this next step.”

About Merck Animal Health
For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook, and Twitter at @MerckAH.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).